Cogent Biosciences (COGT) vs Grifols S.A. (GRFS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Grifols S.A. (GRFS) over the past year, gaining 95.2% versus a loss of 21.8%. Over five years, COGT leads with a +226.2% price change compared with -47.3% for GRFS. Cogent Biosciences is the larger company by market cap ($5.23 billion vs $5.10 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | GRFS |
|---|---|---|
| Share price | $30.14 | $7.50 |
| Market cap | $5.23B | $5.10B |
| 1-day change | -0.79% | -0.27% |
| YTD return | -15.15% | -19.79% |
| 1-year return | +95.21% | -21.79% |
| 5-year return | +226.19% | -47.26% |
| P/E ratio (TTM) | — | 9.74 |
| Forward P/E | — | 5.20 |
| EPS (TTM) | $-2.16 | $0.77 |
| Dividend yield | 0.00% | 1.41% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-328.94M | — |
| 52-week high | $43.73 | $9.90 |
| 52-week low | $13.78 | $6.96 |
| Distance from 52-week high | -31.08% | -24.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +85.20% | +44.93% |
| Average volume | 1.94M | 583.27K |
| Shares outstanding | 173.52M | 258.22M |
| Employees | 258 | 25,258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COGT has outperformed GRFS by 117.0 percentage points over the past year.
- Grifols S.A. offers a meaningfully higher dividend yield (1.41% vs 0.00%).
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
COGT vs GRFS FAQ
Which is bigger, Cogent Biosciences or Grifols S.A.?
Cogent Biosciences (COGT) is larger, with a market capitalization of $5.23B compared with $5.10B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, COGT or GRFS?
COGT returned +95.21% over the past 12 months, compared with -21.79% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Cogent Biosciences or Grifols S.A.?
Grifols S.A. pays a dividend yielding 1.41%, while Cogent Biosciences does not currently pay a regular dividend.
Are Cogent Biosciences and Grifols S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.